PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. The company is headquartered in Redwood City, California.
| Revenue (TTM) | $337.34M |
| Gross Profit (TTM) | $213.75M |
| EBITDA | $-110.08M |
| Operating Margin | -32.10% |
| Return on Equity | -30.20% |
| Return on Assets | -14.70% |
| Revenue/Share (TTM) | $5.99 |
| Book Value | $6.50 |
| Price-to-Book | 3.55 |
| Price-to-Sales (TTM) | 3.42 |
| EV/Revenue | 2.909 |
| EV/EBITDA | -24.58 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 19.30% |
| Shares Outstanding | $57.27M |
| Float | $55.81M |
| % Insiders | 3.49% |
| % Institutions | 97.79% |
Volatility is currently contracting
PROCEPT BioRobotics NASDAQ: PRCT reported 18% revenue growth in the third quarter of 2026 as demand for its HYDROS systems and procedure-related products helped offset slower-than-expected placements at new U.S. accounts.
PROCEPT BioRobotics Corporation (PRCT) Q3 2026 Earnings Call Transcript
SAN JOSE, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended September 30, 2026.
PROCEPT BioRobotics offers Aquablation to help with symptom relief while preserving sexual and urinary functions for patients. PRCT has ongoing HYDROS placements that further expand its commercial potential. That should eventually require replacements and help equipment revenues. In that sense, PRCT's recurring sales with consumables could become increasingly valuable. However, that assumes that procedure growth continues as well.
SAN JOSE, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the third quarter of 2026 after market close on Wednesday, November 4, 2026. The Company's management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SAN DIEGO, Oct. 1, 2026 /PRNewswire/ -- The Shareholders Foundation, Inc. announced that a lawsuit has been filed concerning certain investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT). Investors who purchased shares of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or +1 (858) 779-1554.
A lawsuit was filed for certain investors in PROCEPT BioRobotics Corporation shares. NASDAQ: PRCT investors should contact the Shareholders Foundation
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against PROCEPT BioRobotics Corporation ("PROCEPT" or the "Company") (NASDAQ: PRCT) on behalf of all purchasers of PROCEPT common stock between February 28, 2024 and February 25, 2026 (the "Class Period"). CLICK HERE TO JOIN THE CASE If you are an investor in PROCEPT and have suffered losses, you may CLICK HERE to contact us.
LOS ANGELES, Sept. 22, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises PROCEPT BioRobotics Corporation, (“PROCEPT” or the "Company") (NASDAQ: PRCT) investors of a class action on behalf of investors that bought securities between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.
NEW YORK, Sept. 22, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or "the Company") (NASDAQ: PRCT ) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PRCT and any ticker you trade — then tracks every position and per-strategy win rate.
